Study to Evaluate the Immunogenicity and Safety of a Heterologous Vaccine Regimen Against Ebola

PHASE2CompletedINTERVENTIONAL
Enrollment

699

Participants

Timeline

Start Date

December 18, 2019

Primary Completion Date

April 25, 2020

Study Completion Date

October 12, 2022

Conditions
Ebola Virus Disease
Interventions
BIOLOGICAL

Ad26.ZEBOV vaccine

The booster vaccination with Ad26.ZEBOV (5x10\^10 vp, same dosage as during the first dose) will be given at 1 year after the first dose or 2 years post-first dose.

Trial Locations (1)

Unknown

Hôpital Général de Référence de Boende, Boende

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Johnson & Johnson

INDUSTRY

collaborator

Ace Africa

OTHER

collaborator

Innovative Medicines Initiative

OTHER

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

collaborator

University of Kinshasa

OTHER

lead

Universiteit Antwerpen

OTHER